https://stanfordhealthcare.org/publications/895/895832.html
895832 | Stanford Health Care
Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001+irinotecan vs. regorafenib plus irinotecan in third/four
stanfordhealthcare